Joel H Rubenstein, MD, MSc, AGAF, FACG, FASGE

 Joel Rubenstein
Professor of Internal Medicine and Program Director
Fellowship - Advanced Esophageal, Medical School
[email protected]
Available to mentor
Joel H Rubenstein, MD, MSc, AGAF, FACG, FASGE
Joel Rubenstein
Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      e-Health and Artificial Intelligence Initiative
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Rogel Cancer Center

    Recent Publications

     See All Publications
    • Journal Article
      Mo1134 THE BOSS TRIAL WAS LIKELY UNDERPOWERED FOR ITS PRIMARY OUTCOME OF OVERALL MORTALITY REDUCTION: A MODELING STUDY
      Yoon JY, van den Berg DM, Lim F, Omidvari AH, Agyekum A, Inadomi JM, Curtius K, Lansdorp-Vogelaar I, Hur C, Rubenstein JH. Gastrointestinal Endoscopy, 2026 May 2; 103 (5): s - 780. DOI:10.1016/s0016-5107(26)02054-7
    • Journal Article
      Mo1134 THE BOSS TRIAL WAS LIKELY UNDERPOWERED FOR ITS PRIMARY OUTCOME OF OVERALL MORTALITY REDUCTION: A MODELING STUDY
      Yoon JY, van den Berg DM, Lim F, Omidvari AH, Agyekum A, Inadomi JM, Curtius K, Lansdorp-Vogelaar I, Hur C, Rubenstein JH. Gastroenterology, 2026 May 7; 170 (6): s - 780. DOI:10.1016/s0016-5085(26)02123-2
    • Journal Article
      Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
      Sawas T, Davitkov P, Zhou M, Eluri S, Leiman DA, Thrift AP, Singh S, Inadomi J, Katzka D, Rubenstein JH, Stachler M, Wani S. Am J Gastroenterol, 2026 Feb 25; DOI:10.14309/ajg.0000000000003977
      PMID: 41738629
    • Journal Article
      AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus
      Wani S, Zhou MJ, Sawas T, Rubenstein JH, Eluri S, Leiman DA, Sultan S, Singh S, Inadomi J, Thrift AP, Katzka DA, Davitkov P. Gastroenterology, 2025 Nov 1; 169 (6): 1184 - 1231. DOI:10.1053/j.gastro.2025.09.012
    • Proceeding / Abstract / Poster
      265. THE COST-EFFECTIVENESS OF RISK-BASED MANAGEMENT OF BARRETT’S ESOPHAGUS PATIENTS USING TISSUECYPHER OR P53 BIOMARKERS: A MICROSIMULATION STUDY
      van den Berg DMN, Omidvari A-H, Rubenstein JH, Inadomi JM, de Jonge L, Lansdorp-Vogelaar I. Diseases of the Esophagus, 2025 Aug 15; 38 (Supplement_1): doaf061.325 DOI:10.1093/dote/doaf061.325
    • Proceeding / Abstract / Poster
      268. COST-EFFECTIVENESS OF SCREENING FOR BARRETT’S ESOPHAGUS WITH ESOCHECK/ESOGUARD COMPARED TO SCREENING WITH UPPER ENDOSCOPY
      van den Berg DMN, Omidvari A-H, Lim F, Rubenstein JH, Inadomi JM, Hur C, Greer KB, de Jonge L, Lansdorp-Vogelaar I. Diseases of the Esophagus, 2025 Aug 15; 38 (Supplement_1): doaf061.042 DOI:10.1093/dote/doaf061.042
    • Proceeding / Abstract / Poster
      1110: VALIDATION OF THE KETTLES ESOPHAGEAL AND CARDIA ADENOCARCINOMA PREDICTION TOOL FOR IDENTIFYING BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA
      Rubenstein JH, Burns J, Arasim M, Evans R. Gastroenterology, 2025 Jul 4; 169 (1): s-265-s-266 DOI:10.1016/s0016-5085(25)01558-6
    • Proceeding / Abstract / Poster
      Sa1089: THE COST-EFFECTIVENESS OF RISK-BASED MANAGEMENT OF BARRETT’S ESOPHAGUS PATIENTS USING TISSUECYPHER OR P53 BIOMARKERS: A MICROSIMULATION STUDY
      van den Berg DM, Omidvari AH, Rubenstein JH, Inadomi JM, De Jonge L, Lansdorp-Vogelaar I. Gastroenterology, 2025 Jul 4; 169 (1): s - 349. DOI:10.1016/s0016-5085(25)01739-1

    Featured News & Stories

         red cells clustered together inside body black light up blue see through
    Health Lab

    Understanding esophageal cancer

    In this Q&A, a Michigan Medicine doctor talks about esophageal cancer, its signs and risk factors to know.